-
Publication Venue For
-
Enrollment in clinical trials according to patients race: experience from the VA Cooperative Studies Program (1975-2000)..
25:378-387.
2004
-
Data monitoring and large apparent treatment effects..
25:67-69.
2004
-
A randomized trial of colpopexy and urinary reduction efforts (CARE): design and methods..
24:629-642.
2003
-
Constructing a database of individual clinical trials for longitudinal analysis..
24:324-340.
2003
-
Toward protecting the safety of participants in clinical trials..
24:256-271.
2003
-
Leading the Way in Exercise and Diet (Project LEAD): intervening to improve function among older breast and prostate cancer survivors..
24:206-223.
2003
-
A note on statistical methods for assessing therapeutic equivalence..
23:515-520.
2002
-
Graphical search for two-stage designs for phase II clinical trials..
22:367-372.
2001
-
Knowledge of fraud among biostatisticians..
22:263-264.
2001
-
Fraud in medical research: an international survey of biostatisticians. ISCB Subcommittee on Fraud..
21:415-427.
2000
-
A multicenter, randomized trial of percutaneous coronary intervention versus bypass surgery in high-risk unstable angina patients. The AWESOME (Veterans Affairs Cooperative Study #385, angina with extremely serious operative mortality evaluation) investigators from the Cooperative Studies Program of the Department of Veterans Affairs..
20:601-619.
1999
-
Data monitoring committees and interim monitoring guidelines..
20:395-407.
1999
-
A design alternative for two-stage, phase II, multicenter cancer clinical trials..
19:440-450.
1998
-
Guidelines for quality assurance in multicenter trials: a position paper..
19:477-493.
1998
-
Cooperative studies in health services research in the Department of Veterans Affairs..
19:134-148.
1998
-
Developing systems for cost-effective auditing of clinical trials..
18:651-660.
1997
-
A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931..
18:286-300.
1997
-
Erratum: (Controlled Clinical Trials, Volume 14, Number 6, December 1993, page 511, 512, 515).
15:326.
1994
-
Sample size requirements and length of study for testing interaction in a 2 x k factorial design when time-to-failure is the outcome [corrected]..
14:511-522.
1993
-
Design, methods, and conduct of the Optic Neuritis Treatment Trial..
14:123-142.
1993
-
Ethical dilemmas in continuing a zidovudine trial after early termination of similar trials..
14:6-18.
1993
-
Suspended judgment. Clinical trials of informed consent..
13:321-324.
1992
-
Methods, statistical features, and baseline results of a standardized, multicentered ophthalmologic surgical trial: the Silicone Study..
12:438-455.
1991
-
Cost and quality of life outcomes in the TAMI 5 trial: The primacy of secondary endpoints.
11:268.
1990
-
·P-18 Need an endpoint for a clinical trial? Just ask.
11:284.
1990
-
Monitoring versus interim analysis of clinical trials: a perspective from the pharmaceutical industry..
10:57-70.
1989
-
Use of ejection fraction as a surrogate endpoint for death in clinical trials of acute myocardial infraction.
10:349.
1989
-
Utilization of the National Death Index-A classification problem. Impact of changes in the NDI matching criteria evaluated with the Coronary Artery Surgery Study (CASS) data.
9:242.
1988
-
Admissible two-stage designs for phase II cancer clinical trials
2003
-
USE OF CUMULATIVE WITHDRAWAL RATES IN THE EVALUATION OF SAFETY AND EFFICACY IN A LONG-TERM CONTROLLED CLINICAL-TRIAL
1983